Will 2022 be the year of medtech M&A. EY’s John Babitt joins us to talk about acquisition trends and deal-making activity in the latest episode of Let’s Talk Medtech.

Omar Ford

January 27, 2022

1 Min Read
John Babitt EY.jpg
Image Courtesy of EY

Medtech M&A took off in 2021 and if there’s any indication to the recent earnings reports that came out, 2022 could be an even bigger year.  John Babitt, a Life Science Partner with EY joins us for this episode of Let’s Talk Medtech for a candid conversation regarding M&A.

Babitt speaks on trends reported in EY’s Annual M&A Firepower Report. Click here for a transcript of the first 1,000 words of Let’s Talk Medtech’s conversation with John Babitt, and check below for the full episode.

 

 

About the Author(s)

Omar Ford

Omar Ford is MD+DI's Editor-in-Chief. You can reach him at [email protected].

 

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like